That's not what you asked. So you have an actual understanding what Sanofi got here. VBIV reformulated the Sanofi vaccine so that it could be stored at lower temperatures, LPV technology. . This is a vaccine that SF was working on. This is win/win for VBIV. If SF validates that the platform works, they will pay a royalty.
LPV belongs to VBIV and is protected to 2030. SF wants to be able to ship their product around the world at some point, LVP allows them to do it without the rigorous storage problems that all vaccines have related to them.
The beauty of this, the vaccine is in the clinic. So we not only may see a royalty one day, we also are gaining a validating partner that the technology works.
Purchasing rights? What is that? You really do not have a clue of what they licensed and why, do you?
Show us a brain, one time.
You will never know the collaboration plans, because they are confidential. I would bet you have no understanding of what technology they are even using of vbiv. Only rory would describe this as purchasing rights.
You are stupid, I will give you that.
Dumb question. Why would the collaboration dissolve, with merger? Maybe we will ask Arlo to ask the dumb questions, since he thought this one up, using your id.
VBIV was able to show that after 1 year at 40 degrees C, that the drug still had it's potency. The cost to store adds about 20% to the vaccine. Now how much could VBIV charge every vaccine company for this technology? How flu shots are given every year around the world. This cost could easily be passed on, by eliminating the need to cold store to transport or have on the shelf. 6B people in the world, if 10% get a vaccine a year and you could charge just $2 for the technology, that is $1.2B a year. I would wager that more then 600M vaccines are administered per year. On VBIV web page, it's states that proof of concept is complete on testing.
What if you could get a piece of every vaccine even if you don't sell it. This also may move into regular drugs that also need to be cold stored.
Flu shots fact sheet from FDA:
Storing Influenza Vaccine
Store influenza vaccine in the refrigerator at 35° to 46°F (2 to 8°C). Never expose influenza vaccine to freezing temperatures.
Place the vaccine in the center of the refrigerator, away from the freezer compartment, the back wall, and the bottom of the refrigerator where the temperature is usually colder. The vaccine should be far enough away from the freezer compartment so there is no risk of it freezing.
Never store vaccines in the door of the refrigerator or the door of the freezer. This would expose the vaccine to wide temperature variations.
Equip the refrigerator with its own certified and calibrated thermometer. Check and log the temperature in the refrigerator at least once each day and adjust the control slightly if the thermometer indicates that the temperature is close to either of the two extremes (35° and 46°F).
Place filled plastic water jugs in the refrigerator to help maintain temperature stability. This helps keep temperatures uniform and provides additional cold mass, both of which are useful, particularly if there is a power outage.
Safeguard the electrical supply to the refrigerator. Make sure the refrigerator outlet has a safety lock plug. Label the refrigerator, electrical outlets, fuses, and circuit breakers on the power circuit with information that clearly identifies the perishable nature of the vaccine and the immediate steps to be taken in case of interruption of power.
Shipping Influenza Vaccine
Vaccine may be carefully transported in insulated containers with cold/ice packs on the bottom and top of the container. Four layers of heavy wrapping paper must be used between the cold/ice packs and the boxes/vials of vaccine. Vaccine CANNOT be touching the ice during shipping.
A thermometer should be included in the container and checked when the insulated container is opened upon arrival.
CMV and RSV are the two great targets. First they have catch up markets. This is a nice way of describing how once this drug gets approved, the demand is greatest in the early years. You are catching up with all the unprotected mothers. They should explain this in the CC. But the best way to view it, if you had a market potential of $2B, you could expect the early years to be $3B, because you have to also protect someone who is in the child bearing years. Down the road,females will have gotten this protection as infants and not need a shot later, like when this drug first gets approved. That is why it's described as catch up market.
The CMV trial will enroll 125 pts. Ph1 has a second end point and that target should have some results 10 months into it, so maybe by this time next year, we are getting some nice news.
LPV and Vac-b could be the first thing they address as merged companies. My hope is they get this deal done before EOY.
This combination has all the attributes of a large pharma buyout down the road. Each of the main players, each took 500M share deals, that kind of hints that they are putting this together as POC and then peddle it.
Wouldn't take much success to spark interests here. You have a lead drug approved, with a great tract record and need out there. You have a pipeline and you have two discovery platforms.
You care. You are the math idiot who started bragging you bought at .25 after the split and that somehow your average went down. When i corrected you, you threw a hissy fit.
I never post to my self, you read every thing. Just which ID you decide to use, to show you are stupid, is the thing we wait for. Now your 15 minutes are up. You were too stupid to know simple math, you are too stupid, to give you any more time. Now go change arlo's diaper. Do something useful.
Yes, you do chucky, you just use a different id. You are the second dumbest math id of rory's. K9uwa was number one. Don't take this as I will reply to anything else. I choose when I will post and where.
Serious thought here. With so many refugee's moving around, the need to be protected from Hep b is greater today then anytime. How many are crossing our boarders carrying this virus? Europe getting huge amount crossing their boarders. Hep B is 100 greater then HIV in the amount of carriers.
The USA is going to have to address this and svac-b is almost 100% effective. There is evidence our drug not only protects, but also can be used as a maintenance drug. It ramps up faster then the current SOC.
Awareness is what is needed. I see a day where everyone is wearing a yellow band. Hep B is widespread and there is something that can be done about it.
This group is ignorant. Arlo and his pals only know how to place their thumbs on any intelligent posts.